June 9, 2009. NCHR was disappointed by the quality of the research presented for these three drugs, and the FDA’s failure to clearly present those shortcomings in this meeting.
Read More »On Medical Treatments & Products
Statement of NCHR At the April 8, 2009 FDA Psychopharmacologic Drugs Advisory Committee Meeting Regarding Seroquel XR
April 8, 2009. We testified arguing that Seroquel, an Antipsychotic medication, should be kept off the market as it has not been conclusively proven that it does not increase the risk of diabetes or tardive dyskinesia.
Read More »NCHR Testimony on Seroquel XR
April 8, 2009. The benefits are statistically significant in most, but not all the studies provided to the FDA. But, let’s be clear here: the patients on placebo are improving greatly in these studies – almost as much as those taking Seroquel.
Read More »NCHR Testimony on Fablyn
September 8, 2008. Osteoporosis is a serious disease. Fortunately, there are numerous treatments available, and those options should help the FDA determine whether the risks of this drug, Fablyn, outweigh the benefits.
Read More »NCHR Testimony at FDA on the NeuroStar TMS System for Major Depression
January 26, 2007. Depression is a serious and debilitating disease. The use of ineffective treatments can contribute to feelings of hopelessness, which in turn can worsen the symptoms and even result in suicide.
Read More »